Rising Cases of Cancer to Heighten Pediatric Neuroblastoma Treatment Sales: Fact.MR
Increasing cases of cancer among infants to bolster the sales for pediatric neuroblastoma treatment market
Fact.MR, Rockville MD: Award winning market research company Fact.MR has conducted a research study on global pediatric neuroblastoma treatment market. As per its analysis, a positive growth outlook is expected through 2021, primarily underpinned by increasing cases of cancer and manufacturers to conduct an in-depth research. Manufacturing companies are leveraging their production capacities in order to develop an immunity should an infection arise.
According to WHO, nearly 6% of children, especially in regions like United States accounts for affecting the infants. Hence, fostering the demand for the pediatric neuroblastoma treatment.
According to the latest study by World Health Organization, every year approximately 400,000 children are affected and diagnosed with cancer. With the most common types being, leukemia, brain cancers, lymphomas. Hence, accelerating the demand for the market.
“Prominent manufacturers are developing new strategies such as product launch to embark on a positive growth journey. Following the outbreak of COVID-19, the increasing cases of cancer are anticipated to bolster the demand for pediatric neuroblastoma,” says the Fact.MR analyst.
For More Valuable Information on Regional Market Dynamics, Request a Report Sample
https://www.factmr.com/connectus/sample?flag=S&rep_id=4694
Key Takeaways
- Global pediatric neuroblastoma treatment is anticipated to surge at nearly 9.2% CAGR through 2021
- North America to retain its dominance owing to the high adoption rate of technologically-advanced products
- North America to exhibit a staggering sales at a CAGR of nearly 9%
- High sales of chemotherapy segment to spearhead the pediatric neuroblastoma treatment market growth
- Immunotherapy to witness high growth in the therapy segment, attributed to increased survival rates of the patients
- Europe to emerge as a promising region for pediatric neuroblastoma treatment, owing to rising drug approvals and incidences of neuroblastoma
Prominent Drivers
- R&D activities by biotechnology companies focusing on neuroblastoma research to propel the demand
- Manufacturers are focusing on new product launches as the key factor to drive the sales for pediatric neuroblastoma treatment
- High technological advancements and provision of orphan drugs aiding the process of approval to foster the growth
Key Restraints
- Side effects such as hearing loss, fertility problems and emotional/psychological issues to hamper the demand
- Problems with bones and muscles such as scoliosis due to the treatment, thus restraining growth
Discover more about the pediatric neuroblastoma treatment market with figures, data tables and the table of contents. You will also find detailed market segmentation on https://www.factmr.com/report/4694/pediatric-neuroblastoma-treatment-market
Competitive Landscape
Key manufacturers operating in the global pediatric neuroblastoma treatment market include United Therapeutics Corporation, APEIRON Biologics AG, Baxter, Cellactar Biosciences Inc., Pfizer Inc., MacroGenics Inc., and Bayer AG. The primary strategy that all the manufacturers are focusing is the increased investment in the development of new products.
In February 2021, United Therapeutics announced commercial launch of the Remunity® Pump For Remodulin® for patients with pulmonary arterial hypertension. The product was initially cleared by the FDA in May 2019 with the instructions for patients filling. An additional clearance in 2020 enabled the efficiency and improved the convenience for patients.
Collaborations and acquisitions with other manufacturers also helps manufacturers cement their presence in the market. For instance, in November 2020, APEIRON Biologics AG and Domainex Ltd announced the expansion of their partnership to progress targeted cancer immune therapy drug discovery.
For in-depth Competitive Analysis, Ask Here
https://www.factmr.com/connectus/sample?flag=RM&rep_id=4694
More Insights on the Pediatric neuroblastoma treatment Market Report
In its latest report, Fact.MR offers unbiased analysis of the global pediatric neuroblastoma treatment market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of therapy-type (immunotherapy, chemotherapy, and others), distribution channel (hospital pharmacies, and retail pharmacies & drug stores), and across major regions (North America, Europe and Rest of the World)
Explore Fact.MR’s Coverage on the Healthcare Domain
OTC Pediatric Healthcare Market: Fact.MR’s exclusive coverage on the global OTC Pediatric Healthcare market sheds light on the prominent expansion dynamics likely to play a pivotal role in furthering future growth. A detailed segment-wise and regional assessment has been embedded within the scope of this study, along with an exhaustive profiling of prominent microscopy device manufacturers present in the landscape.
Pediatric Chronic Rhinosinusitis Market: An extensive study by Fact.MR on the global Pediatric Chronic Rhinosinusitis market, analyses crucial trends which determine future expansion prospects of the landscape. Details regarding prominent manufacturers and segments across prominent regions have also been provided in this study.
Pediatrics Orthotics Market: A detailed assessment of Pediatrics Orthotics market value chain analysis, business execution, and supply chain analysis across the regional markets has been covered in Fact.MR’s coverage on the landscape. A comprehensive estimate on asthma spacers market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of asthma spacers market during the forecast period.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
Sudip Saha
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583